M&A
confidence high
sentiment positive
materiality 0.60
Amphastar files BAQSIMI financials: 2022 revenue $139.3M, revenue less direct expenses $59.8M
Amphastar Pharmaceuticals, Inc.
- BAQSIMI 2022 revenue $139.3M (up 23% YoY from $113.2M); revenue less direct expenses $59.8M vs -$2.3M in 2021.
- Q1 2023 revenue $31.4M, up 7.5% YoY from $29.2M; revenue less direct expenses $13.0M vs $9.2M.
- Acquisition terms: $500M cash at closing, $125M at one-year anniversary, plus up to $450M in sales milestones.
- Net intangible assets of BAQSIMI were $100.3M as of Dec 31, 2022; total assets acquired $187.6M.
- Audited abbreviated financial statements cover FY 2021-2022; unaudited for Q1 2023 and 2022.